Published Date:2023-08-02 Original Link:https://www.onenessbio.com/en/news_detail236_2.htm No 1 Date of announcement 2023/08/02 Time of announcement 21:48:19 Subject SNS812, a broad-spectrum siRNA for COVID-19 infection, co-developed by Oneness & Microbio (Shanghai) has been agreed by US FDA to proceed with Phase 2 clinical trial. To which item it meets paragraph 10 Date of events 2023/08/02 Statement Product:SNS812, a...Read More